| Dr Charles Scott Weston, MD | |
|
230 Main St, Agawam, MA 01001-1838 | |
| (413) 789-6800 | |
| (413) 786-0913 |
| Full Name | Dr Charles Scott Weston |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 33 Years |
| Location | 230 Main St, Agawam, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053379248 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 82092 (Massachusetts) | Secondary |
| 207R00000X | Internal Medicine | 82092 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Caretenders | Holyoke, MA | Home health agency |
| Comfort Plus Caregivers Llc | East longmeadow, MA | Home health agency |
| Baystate Home Health | Springfield, MA | Home health agency |
| Baystate Vna And Hospice | Springfield, MA | Hospice |
| Mercy Medical Ctr | Springfield, MA | Hospital |
| Baystate Medical Center | Springfield, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Riverbend Medical Group Inc | 5698064343 | 159 |
News Archive
Research published yesterday indicates that recurrence of human papillomavirus (HPV)-induced cancers affecting the oropharynx (the area of the throat just behind the mouth) can be predicted by blood and saliva tests that screen for DNA fragments from HPV that have been shed by cancer cells.
The largest study to correlate genetics with response to cancer drugs releases its first results today. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples to 18 anticancer therapeutics.
A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.
"Data showing how a hospital performs on certain measures [of post-surgical infection prevention] are publicly available. But, a study published in [the Journal of the American Medical Association] says, the publicly reported measures don't actually correlate with postop infection rates. In other words, picking your hospital on the basis of how often it administers antibiotics within an hour before surgery is not going to help you avoid an infection" (Hobson, 6/22).
Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters.
› Verified 7 days ago
| Entity Name | Riverbend Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841651197 PECOS PAC ID: 5698064343 Enrollment ID: O20160614001710 |
News Archive
Research published yesterday indicates that recurrence of human papillomavirus (HPV)-induced cancers affecting the oropharynx (the area of the throat just behind the mouth) can be predicted by blood and saliva tests that screen for DNA fragments from HPV that have been shed by cancer cells.
The largest study to correlate genetics with response to cancer drugs releases its first results today. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples to 18 anticancer therapeutics.
A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.
"Data showing how a hospital performs on certain measures [of post-surgical infection prevention] are publicly available. But, a study published in [the Journal of the American Medical Association] says, the publicly reported measures don't actually correlate with postop infection rates. In other words, picking your hospital on the basis of how often it administers antibiotics within an hour before surgery is not going to help you avoid an infection" (Hobson, 6/22).
Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles Scott Weston, MD 230 Main St, Agawam, MA 01001-1838 Ph: (413) 789-6800 | Dr Charles Scott Weston, MD 230 Main St, Agawam, MA 01001-1838 Ph: (413) 789-6800 |
News Archive
Research published yesterday indicates that recurrence of human papillomavirus (HPV)-induced cancers affecting the oropharynx (the area of the throat just behind the mouth) can be predicted by blood and saliva tests that screen for DNA fragments from HPV that have been shed by cancer cells.
The largest study to correlate genetics with response to cancer drugs releases its first results today. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples to 18 anticancer therapeutics.
A team of investigators at Brown University has developed a novel way to treat a class of breast cancer cells. The team has created twin nanoparticles that specifically targets the Her-2 tumor cell and unload a cancer-fighting drug directly into it. The result is a boost in antitumor activity while minimizing side effects. The findings of this study have been published in the Journal of the American Chemical Society.
"Data showing how a hospital performs on certain measures [of post-surgical infection prevention] are publicly available. But, a study published in [the Journal of the American Medical Association] says, the publicly reported measures don't actually correlate with postop infection rates. In other words, picking your hospital on the basis of how often it administers antibiotics within an hour before surgery is not going to help you avoid an infection" (Hobson, 6/22).
Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters.
› Verified 7 days ago
Matthew J. Kane, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 230 Main St, Agawam, MA 01001 Phone: 413-789-6800 Fax: 413-789-8048 | |
Daniel W. Weiswasser, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 230 Main St, Agawam, MA 01001 Phone: 413-789-8010 Fax: 413-789-5171 | |
Christina Hayfron-benjamin, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 Main St, Agawam, MA 01001 Phone: 413-789-6800 Fax: 413-789-5171 | |
James Paul Gallagher, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 61 Cooper St, Agawam, MA 01001 Phone: 413-786-8000 Fax: 413-786-2124 | |
Irene N Cody, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 230 Main St, Agawam, MA 01001 Phone: 413-789-6800 Fax: 413-789-5171 |